Greenlight Capital’s third-quarter investor letter had almost nothing good to say about the hot AI trend, but it does have faith in a tiny biotech.
www.marketwatch.com
#David #Einhorns #Greenlight #prefers #tiny #biotech #excitement
Why David Einhorn’s Greenlight prefers this tiny biotech over AI ‘excitement’
